Early Detection of Anal Cancer Recurrence through HPV ctDNA Monitoring

Strategic Insights -

Researchers at the University of Texas MD Anderson Cancer Center have made a breakthrough in understanding the optimal time point for monitoring human papillomavirus (HPV) circulating tumor DNA (ctDNA) as a prognostic biomarker for localized anal cancer. According to the study, detecting HPV ctDNA three months after chemoradiation is associated with recurrence in patients with stages I to III anal cancer.

Key Takeaways:

  • The study evaluated 137 patients with anal cancer treated with chemoradiation between December 2020 and March 2024.
  • The patients were monitored for HPV ctDNA status at baseline, at the end of chemoradiation, and during surveillance.
  • Detection of HPV ctDNA at ≥3 months after chemoradiation was associated with recurrence (80% vs. 2%), with an odds ratio of 168 (95% confidence interval, 13.6-2,080).
  • The researchers concluded that future clinical trials should incorporate the 3-month post-treatment time point to identify patients with HPV-positive anal cancer at elevated recurrence risk according to HPV ctDNA status.
  • The study received funding from the NIH National Cancer Institute (NCI), MD Anderson team, University of Texas MD Anderson Cancer Center HPV Moon Shots Program, NIH National Cancer Institute (NCI), Cancer Prevention & Research Institute of Texas, and Andrew Sabin Fellow Family Foundation.
  • The researchers suggest that identifying patients at high risk of recurrence could improve treatment outcomes and reduce the risk of cancer progression.

Statistics:

  • 137 patients with stages I to III anal cancer were evaluated in the study.
  • 80% of patients with detectable HPV ctDNA at ≥3 months after chemoradiation experienced recurrence.
  • The odds ratio of recurrence was 168 (95% confidence interval, 13.6-2,080) in patients with detectable HPV ctDNA at ≥3 months.
  • The study assessed HPV ctDNA status at three time points: baseline, end of chemoradiation, and during surveillance.

Sources:

  • Clinical Cancer Research, 2025;31(12):2399-2405. (Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA)
  • Health & Medicine Week, July 18, 2025, p 2093. (NewsRx, LLC)